Location of Repository

Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth by Fluvoxamine: Role of Sigma-1 Receptors, IP3 Receptors and Cellular Signaling Pathways

By Tomoko Nishimura, Tamaki Ishima, Masaomi Iyo and Kenji Hashimoto
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2435603
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2004). A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors.
    2. (2008). An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand.
    3. (2000). Ca 2+ signaling via sigma-1 receptors: novel regulatory mechanism affecting intracellular Ca 2+ concentration.
    4. (2005). Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview.
    5. (2001). Differential involvement of the sigma-1 receptor in the anti-amnesic effect of neuroactive steroids, as demonstrated using an in vivo antisense strategy in the mouse.
    6. (2005). FK1706, a novel non-immunosuppressive immunophilin: neurotrophic activity and mechanism of action.
    7. (2003). FK506 potentiates NGF-induced neurite outgrowth via the Ras/Raf/MAP kinase pathway.
    8. (2007). High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [ 11C]SA4503.
    9. (2007). Hyperactive Ras in developmental disorders and cancer.
    10. (1995). In vivo labeling of sigma receptors
    11. (1989). Inositol phosphates and cell signalling.
    12. (1996). Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain.
    13. (1996). Nakazato A
    14. (2001). Nerve growth factor signaling, neuroprotection, and neural repair.
    15. (2002). Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants.
    16. (1994). Neurite outgrowth of PC12 cells is suppressed by wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase.
    17. (2001). Neuroprotective effect of sigma-1 receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is linked to reduced neuronal nitric oxide production.
    18. (2000). Neurosteroids ameliorate conditioned fear stress: an association with sigma receptors.
    19. (2003). Neurotrophins and their receptors: a convergence point for many signaling pathways.
    20. (1998). Not so selective serotonin selective reuptake inhibitors.
    21. (2004). Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis.
    22. (2007). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors.
    23. (1996). PPBP [4-phenyl-1-(4-phenylbutyl) piperidine] decreases brain injury after transient focal ischemia in rats.
    24. (1995). PPBP [4-phenyl-1-(4-phenylbutyl) piperidine], a potent sigma-receptor ligand, decreases brain injury after transient focal ischemia in cats.
    25. (2001). Regulating ankyrin dynamics: Roles of sigma-1 receptors.
    26. (1998). SA 4503: A novel sigma-1 receptor agonist.
    27. (1997). SA4503, a novel cognitive enhancer, with sigma-1 receptor agonistic properties.
    28. (1998). Selective serotonin reuptake inhibitors in affective disorders–I. Basic pharmacology.
    29. (1998). Selective serotonin reuptake inhibitors in affective disorders–II. Efficacy and quality of life.
    30. (2004). Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond.
    31. (2006). Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals.
    32. (2000). Sigma-1 receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine affords neuroprotection from focal ischemia with prolonged reperfusion.
    33. Su TP (2004) Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.
    34. Su TP (2007) Sigma-1 receptor chaperones at the ERmitochondrion interface regulate Ca 2+ signaling and cell survival.
    35. (2002). The antidepressant-like effect induced by the sigma-1 receptor agonist igmesine involves modulation of intracellular calcium mobilization.
    36. (2001). The interaction between neuroactive steroids and the sigma-1 receptor function: behavioral consequences and therapeutic opportunities.
    37. (2005). The role of sigma receptors in depression.
    38. (2006). The sigma-1 protein as a target for the nongenomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects.
    39. (2006). Tolerability and safety of fluvoxamine and other antidepressants.
    40. (1994). Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses.
    41. (2001). Trk receptors: roles in neuronal signal transduction.
    42. (1994). Ullrich A
    43. (2003). Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction.
    44. (1998). Using secondary binding properties to select a not so selective serotonin selective reuptake inhibitor.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.